Effect of chromium on glycemic control among patients with diabetes mellitus attending family medicine clinic, Suez Canal University Hospitals, Ismailia Governorate, Egypt

Moustafa Mahmoud Ahmed; Mosleh Abdel Rahman Ismail; Samar Farag Mohamed; Safwat A. Ahmed; Wael Ahmed Zeid

doi:10.53730/ijhs.v9nS1.14344

Authors

Moustafa Mahmoud Ahmed
Moustafa.Mahmoud@med.svu.edu.eg
Family Medicine Department, Qena Faculty of Medicine, South Valley University
Mosleh Abdel Rahman Ismail Family Medicine Department, Faculty of Medicine, Suez Canal University
Samar Farag Mohamed Family Medicine Department, Faculty of Medicine, Suez Canal University
Safwat A. Ahmed Pharmacognosy Department, Faculty of Pharmacy, Suez Canal University
Wael Ahmed Zeid Family Medicine Department, Faculty of Medicine, Suez Canal University

Keywords:

Diabetes mellitus, chromium, glycemic control, glycosylated hemoglobin

Abstract

Background. Diabetes mellitus is a serious worldwide health issue and a chronic illness. Approximately 463 million persons between the ages of 20 and 79 have diabetes, which accounts for 9.3% of the global population in this age range. With a current national prevalence of 15.2% and 8.9 million people with diabetes, Egypt ranks the ninth out of ten nations in this category. Chromium is a trace and a necessary element, which may decrease glucose tolerance. Objectives: To determine the effect of chromium on glycemic control among patients with diabetes mellitus attending the family medicine clinic, Suez Canal University hospitals, and to identify the reported side effect. Patients and methods: A double blinded randomized controlled clinical trial was conducted at the family medicine clinic, Suez Canal University hospitals in Ismailia Governorate, Egypt. Socioeconomic status was determined using El-Gilany score. Participants were assigned to receive either 200 mcg of chromium picolinate capsule or placebo daily for 12 weeks. Results: Chromium supplements in the intervention group viewed a statistically significant reduction in all glycemic control parameters, in contrast to the control group. There was a statistically significant reduction in fasting blood glucose after 1 month of intervention (P value < 0.05).

Downloads

Download data is not yet available.

References

Donaghue KC, Marcovecchio ML, Wadwa RP, Chew EY, Wong TY, Calliari LE, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Microvascular and macrovascular complications in children and adolescents. Pediatr Diabetes [Internet]. 2018 Oct;19 Suppl 2(Suppl 27):262–74. Available from: https://pubmed.ncbi.nlm.nih.gov/30079595 DOI: https://doi.org/10.1111/pedi.12742

de Boer IH, Bangalore S, Benetos A, Davis AM, Michos ED, Muntner P, et al. Diabetes and Hypertension: A Position Statement by the American Diabetes Association. Diabetes Care [Internet]. 2017;40(9):1273–84. Available from: http://dx.doi.org/10.2337/dci17-0026 DOI: https://doi.org/10.2337/dci17-0026

Group IDFDA. Update of mortality attributable to diabetes for the IDF Diabetes Atlas: Estimates for the year 2013. Diabetes Res Clin Pract [Internet]. 2015;109(3):461–5. Available from: http://dx.doi.org/10.1016/j.diabres.2015.05.037 DOI: https://doi.org/10.1016/j.diabres.2015.05.037

Willis M, Asseburg C, Neslusan C. Conducting and interpreting results of network meta-analyses in type 2 diabetes mellitus: A review of network meta-analyses that include sodium glucose co-transporter 2 inhibitors. Diabetes Res Clin Pract [Internet]. 2019;148:222–33. Available from: http://dx.doi.org/10.1016/j.diabres.2019.01.005 DOI: https://doi.org/10.1016/j.diabres.2019.01.005

Association AD. 11. Microvascular complications and foot care: standards of medical care in diabetes− 2020. Diabetes Care. 2020;43(Supplement_1):S135–51. DOI: https://doi.org/10.2337/dc20-S011

Health NI of. Office of Dietary Supplements. Dietary supplement fact sheet. Availabe online https//ods od nih gov/factsheets/(accessed 25 April 2021). 2006;

El-Gilany A, El-Wehady A, El-Wasify M. Updating and validation of the socioeconomic status scale for health research in Egypt. East Mediterr Heal J [Internet]. 2012;18(9):962–8. Available from: http://dx.doi.org/10.26719/2012.18.9.962 DOI: https://doi.org/10.26719/2012.18.9.962

Farrokhian A, Mahmoodian M, Bahmani F, Amirani E, Shafabakhsh R, Asemi Z. The Influences of Chromium Supplementation on Metabolic Status in Patients with Type 2 Diabetes Mellitus and Coronary Heart Disease. Biol Trace Elem Res [Internet]. 2019;194(2):313–20. Available from: http://dx.doi.org/10.1007/s12011-019-01783-7 DOI: https://doi.org/10.1007/s12011-019-01783-7

Maret W. 9. CHROMIUM SUPPLEMENTATION IN HUMAN HEALTH, METABOLIC SYNDROME, AND DIABETES [Internet]. Essential Metals in Medicine: Therapeutic Use and Toxicity of Metal Ions in the Clinic. De Gruyter; 2019. p. 231–52. Available from: http://dx.doi.org/10.1515/9783110527872-009 DOI: https://doi.org/10.1515/9783110527872-009

Asbaghi O, Fatemeh N, Mahnaz RK, Ehsan G, Elham E, Behzad N, et al. Effects of chromium supplementation on glycemic control in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res [Internet]. 2020;161:105098. Available from: http://dx.doi.org/10.1016/j.phrs.2020.105098 DOI: https://doi.org/10.1016/j.phrs.2020.105098

Zhao M, Ge X, Xu J, Li A, Mei Y, Zhao J, et al. Negatively interactive effect of chromium and cadmium on obesity: Evidence from adults living near ferrochromium factory. Ecotoxicol Environ Saf [Internet]. 2022;231:113196. Available from: http://dx.doi.org/10.1016/j.ecoenv.2022.113196 DOI: https://doi.org/10.1016/j.ecoenv.2022.113196

Talab AT, Abdollahzad H, Nachvak SM, Pasdar Y, Eghtesadi S, Izadi A, et al. Effects of Chromium Picolinate Supplementation on Cardiometabolic Biomarkers in Patients with Type 2 Diabetes Mellitus: a Randomized Clinical Trial. Clin Nutr Res [Internet]. 2020 Apr 24;9(2):97–106. Available from: https://pubmed.ncbi.nlm.nih.gov/32395440 DOI: https://doi.org/10.7762/cnr.2020.9.2.97

Zhao F, Pan D, Wang N, Xia H, Zhang H, Wang S, et al. Effect of Chromium Supplementation on Blood Glucose and Lipid Levels in Patients with Type 2 Diabetes Mellitus: a Systematic Review and Meta-analysis. Biol Trace Elem Res [Internet]. 2021;200(2):516–25. Available from: http://dx.doi.org/10.1007/s12011-021-02693-3 DOI: https://doi.org/10.1007/s12011-021-02693-3

Brownley KA, Boettiger CA, Young L, Cefalu WT. Dietary chromium supplementation for targeted treatment of diabetes patients with comorbid depression and binge eating. Med Hypotheses [Internet]. 2015/03/27. 2015 Jul;85(1):45–8. Available from: https://pubmed.ncbi.nlm.nih.gov/25838140 DOI: https://doi.org/10.1016/j.mehy.2015.03.020

Yin R V, Phung OJ. Effect of chromium supplementation on glycated hemoglobin and fasting plasma glucose in patients with diabetes mellitus. Nutr J [Internet]. 2015 Feb 13;14:14. Available from: https://pubmed.ncbi.nlm.nih.gov/25971249 DOI: https://doi.org/10.1186/1475-2891-14-14

Hamilton EM, Young SD, Bailey EH, Watts MJ. Chromium speciation in foodstuffs: A review. Food Chem [Internet]. 2018;250:105–12. Available from: http://dx.doi.org/10.1016/j.foodchem.2018.01.016 DOI: https://doi.org/10.1016/j.foodchem.2018.01.016

Khodavirdipour A, Haddadi F, Keshavarzi S. Chromium Supplementation; Negotiation with Diabetes Mellitus, Hyperlipidemia and Depression. J Diabetes Metab Disord [Internet]. 2020 Mar 5;19(1):585–95. Available from: https://pubmed.ncbi.nlm.nih.gov/32550211 DOI: https://doi.org/10.1007/s40200-020-00501-8

Jeejeebhoy KN. The Role of Chromium in Nutrition and Therapeutics and As a Potential Toxin. Nutr Rev [Internet]. 2009;57(11):329–35. Available from: http://dx.doi.org/10.1111/j.1753-4887.1999.tb06909.x DOI: https://doi.org/10.1111/j.1753-4887.1999.tb06909.x